TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2021 - 2026)

TriSalus Life Sciences has reported Net Income towards Common Stockholders for 6 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 113.88% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$58.5 million (down 92.95% YoY), and the FY2025 full-year result was -$69.7 million, down 109.7% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.9 million in Q2 2022, with the low at -$41.3 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$11.6 million across 5 years, with a median of -$9.2 million in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 2419.36% in 2022 against a maximum downside of 4565.49% in 2022.
• TriSalus Life Sciences' Net Income towards Common Stockholders stood at -$25.4 million in 2022, then slumped by 43.62% to -$36.4 million in 2023, then jumped by 70.11% to -$10.9 million in 2024, then advanced by 10.45% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$41.3 million (Q3 2025), per Business Quant data.